Dyax Corp. (DYAX) Announces Major Third Quarter Revenue Increase
Dyax Corporation, a Massachusetts biopharmaceutical company, has announced third quarter revenues of $5.5 million, compared with $2.6 million for the comparable quarter in 2007, an increase of 111%. In addition, revenues for the nine-month period ending September 30, 2008, increased to $12.0 million, compared to $7.9 million for the comparable nine-month period in 2007, an increase of nearly 52%. The dramatic increase in revenue was due largely to returns from license and collaboration agreements, including $2.5 million received under the company’s Licensing & Funded Research Program (LFRP). Dyax has also received $38.2 million from licensing and collaboration agreements for its…